Shots: The NMPA’s approval follows its PR pathway and is based on P-III FLAURA study assessing Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib [150mg, qd]/gefitinib [250mg, qd]) in 556 previously untreated […]readmore
Tags : EGFR Mutated Non-Small Cell Lung Cancer